Development and validation of an LC-MS/MS method for simultaneous determination of SH-1028, an irreversible third-generation EGFR TKI, and two of its metabolites in human plasma: application in clinical pharmacokinetics-Reference-Cited by-同舟云学术

Development and validation of an LC-MS/MS method for simultaneous determination of SH-1028, an irreversible third-generation EGFR TKI, and two of its metabolites in human plasma: application in clinical pharmacokinetics

Published:2023-02-01 Issue:2 Volume:53 Page:84-92
ISSN:0049-8254
Container-title:Xenobiotica
language:en
Short-container-title:Xenobiotica

Author:

Zhou Sufeng¹,Sha Bijun¹²,Wang Lu¹,Zhao Yuqing¹,Wang Zhiqiang³,Zhang Xian³,Han Luwei³,Shao Feng¹⁴,Chen Xijing²

Affiliation:

1. Phase I Clinical Trial Unit, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

2. Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China

3. Nanjing Sanhome Pharmaceutical Co., Ltd., Nanjing, China

4. Department of Clinical Pharmacology, Pharmacy College, Nanjing Medical University, Nanjing, China

Funder

Sanhome Pharmaceutical Co., Ltd

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00498254.2023.2183367

Reference16 articles.

1. Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor

2. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial

3. SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer

4. Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis

5. Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors